Leo Pharma Enters into a Sub-Licensing Agreement with Bausch Health to Develop and Commercialize Brodalumab for Moderate-to-Severe Psoriasis Outside Europe

 Leo Pharma Enters into a Sub-Licensing Agreement with Bausch Health to Develop and Commercialize Brodalumab for Moderate-to-Severe Psoriasis Outside Europe

Leo Pharma Enters into a Sub-Licensing Agreement with Bausch Health to Develop and Commercialize Brodalumab for Moderate-to-Severe Psoriasis Outside Europe

Shots:

  • Leo Pharma to get exclusive rights to develop & commercialize brodalumab in Australia, Brazil, Egypt, Mexico, Russia and Saudi Arabia for the treatment of moderate-to-severe psoriasis
  • The sub-licensing agreement complements the ongoing licensing agreement b/w Leo & AstraZeneca to develop & commercialize brodalumab in Europe. Bausch Health has the rights to commercialize brodalumab through a licensing agreement with AstraZeneca outside Europe (Ex-Japan & other Asian countries) where Kyowa Kirin hold the rights
  • Brodalumab (marketed as Kyntheum in the EU) is a mAb targeting IL-17 receptor A (IL17R) and has received EMA’s MAA in Jul’2017, currently indicated for moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy

Click here to­ read full press release/ article | Ref: Business Wire | Image: PharmaStar

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post